Berberine alleviates myocardial diastolic dysfunction by modulating Drp1-mediated mitochondrial fission and Ca²⁺ homeostasis in a murine model of HFpEF

Abstract

Heart failure with preserved ejection fraction (HFpEF) displays normal or near-normal left ventricular ejection fraction, diastolic dysfunction, cardiac hypertrophy, and poor exercise capacity. Berberine, an isoquinoline alkaloid, possesses cardiovascular benefits. Adult male mice were assigned to chow or high-fat diet with L-NAME (“two-hit” model) for 15 weeks. Diastolic function was assessed using echocardiography and non-invasive Doppler technique. Myocardial morphology, mitochondrial ultrastructure, and cardiomyocyte mechanical properties were evaluated. Proteomics analysis, autophagic flux, and intracellular Ca²⁺ were also assessed in chow and HFpEF mice. The results show exercise intolerance and cardiac diastolic dysfunction in “two-hit”-induced HFpEF model, in which unfavorable geometric changes such as increased cell size, interstitial fibrosis, and mitochondrial swelling occurred in the myocardium. Diastolic dysfunction was indicated by the elevated E value, mitral E/A ratio, and E/e’ ratio, decreased e’ value and maximal velocity of re-lengthening (–dL/dt), and prolonged re-lengthening in HFpEF mice. The effects of these processes were alleviated by berberine. Moreover, berberine ameliorated autophagic flux, alleviated Drp1 mitochondrial localization, mitochondrial Ca²⁺ overload and fragmentation, and promoted intracellular Ca²⁺ reuptake into sarcoplasmic reticulum by regulating phospholamban and SERCA2a. Finally, berberine alleviated diastolic dysfunction in “two-hit” diet-induced HFpEF model possibly because of the promotion of autophagic flux, inhibition of mitochondrial fragmentation, and cytosolic Ca²⁺ overload.

Keywords

HFpEF / berberine / Drp1 / autophagy / Ca ²⁺

References

[1] Tsutsui H. Recent advances in the pharmacological therapy of chronic heart failure: evidence and guidelines. Pharmacol Ther 2022; 238: 108185

[2] Ho JE, Redfield MM, Lewis GD, Paulus WJ, Lam CSP. Deliberating the diagnostic dilemma of heart failure with preserved ejection fraction. Circulation 2020; 142(18): 1770–1780

[3] Abudureyimu M, Luo X, Wang X, Sowers JR, Wang W, Ge J, Ren J, Zhang Y. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol 2022; 14(5): mjac028

[4] Zheng Y, Ma S, Huang Q, Fang Y, Tan H, Chen Y, Li C. Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease. Kidney Blood Press Res 2022; 47(4): 219–228

[5] Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020; 17(9): 559–573

[6] Zhang Y, Whaley-Connell AT, Sowers JR, Ren J. Autophagy as an emerging target in cardiorenal metabolic disease: from pathophysiology to management. Pharmacol Ther 2018; 191: 1–22

[7] Rosalia L, Ozturk C, Shoar S, Fan Y, Malone G, Cheema FH, Conway C, Byrne RA, Duffy GP, Malone A, Roche ET, Hameed A. Device-based solutions to improve cardiac physiology and hemodynamics in heart failure with preserved ejection fraction. JACC Basic Transl Sci 2021; 6(9–10): 772–795

[8] Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collins S, Deo RC, Gladwin MT, Granzier H, Hummel SL, Kass DA, Redfield MM, Sam F, Wang TJ, Desvigne-Nickens P, Adhikari BB. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute Working Group summary. Circulation 2020; 141(12): 1001–1026

[9] Cai Y, Xin Q, Lu J, Miao Y, Lin Q, Cong W, Chen K. A new therapeutic candidate for cardiovascular diseases: berberine. Front Pharmacol 2021; 12: 631100

[10] Ceylan-Isik AF, Fliethman RM, Wold LE, Ren J. Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Curr Diabetes Rev 2008; 4(4): 320–328

[11] Ai X, Yu P, Peng L, Luo L, Liu J, Li S, Lai X, Luan F, Meng X. Berberine: a review of its pharmacokinetics properties and therapeutic potentials in diverse vascular diseases. Front Pharmacol 2021; 12: 762654

[12] Cao RY, Zhang Y, Feng Z, Liu S, Liu Y, Zheng H, Yang J. The effective role of natural product berberine in modulating oxidative stress and inflammation related atherosclerosis: novel insights into the gut-heart axis evidenced by genetic sequencing analysis. Front Pharmacol 2021; 12: 764994

[13] An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, Gao Y, Xing Y. Promising antioxidative effect of berberine in cardiovascular diseases. Front Pharmacol 2022; 13: 865353

[14] Abudureyimu M, Yu W, Cao RY, Zhang Y, Liu H, Zheng H. Berberine promotes cardiac function by upregulating PINK1/parkin-mediated mitophagy in heart failure. Front Physiol 2020; 11: 565751

[15] Kumar AA, Kelly DP, Chirinos JA. Mitochondrial dysfunction in heart failure with preserved ejection fraction. Circulation 2019; 139(11): 1435–1450

[16] Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, Luo X, Jiang N, May HI, Wang ZV, Hill TM, Mammen PPA, Huang J, Lee DI, Hahn VS, Sharma K, Kass DA, Lavandero S, Gillette TG, Hill JA. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 2019; 568(7752): 351–356

[17] Madikyzy M, Tilegen M, Nazarbek G, Mu C, Kutzhanova A, Li X, Ma C, Xie Y. Honghua extract mediated potent inhibition of COVID-19 host cell pathways. Sci Rep 2022; 12(1): 14296

[18] Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, Donal E, Sade LE, Ernande L, Garbi M, Grapsa J, Hagendorff A, Kamp O, Magne J, Santoro C, Stefanidis A, Lancellotti P, Popescu B, Habib G; 2016–2018 EACVI Scientific Documents Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18(12): 1301–1310

[19] Ren J, Sun M, Zhou H, Ajoolabady A, Zhou Y, Tao J, Sowers JR, Zhang Y. FUNDC1 interacts with FBXL2 to govern mitochondrial integrity and cardiac function through an IP3R3-dependent manner in obesity. Sci Adv 2020; 6(38): eabc8561

[20] Stefani GP, Capalonga L, da Silva LR, Heck TG, Frizzo MN, Sulzbacher LM, Sulzbacher MM, de Batista D, Vedovatto S, Bertoni APS, Wink MR, Dal Lago P. Effects of aerobic and resistance exercise training associated with carnosine precursor supplementation on maximal strength and V̇O_2max in rats with heart failure. Life Sci 2021; 282: 119816

[21] Yu W, Qin X, Zhang Y, Qiu P, Wang L, Zha W, Ren J. Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K/Akt/mTOR-dependent manner. Cardiovasc Diagn Ther 2020; 10(4): 752–769

[22] Xu H, Yu W, Sun S, Li C, Ren J, Zhang Y. TAX1BP1 protects against myocardial infarction-associated cardiac anomalies through inhibition of inflammasomes in a RNF34/MAVS/NLRP3-dependent manner. Sci Bull (Beijing) 2021; 66(16): 1669–1683

[23] Huang H, Li M, Wang Y, Wu X, Shen J, Xiao Z, Zhao Y, Du F, Chen Y, Wu Z, Ji H, Zhang C, Li J, Wen Q, Kaboli PJ, Cho CH, Wang S, Wang Y, He Y, Wu X. Excessive intake of longan arillus alters gut homeostasis and aggravates colitis in mice. Front Pharmacol 2021; 12: 640417

[24] Li J, Li H, Cai S, Bai S, Cai H, Zhang X. CD157 in bone marrow mesenchymal stem cells mediates mitochondrial production and transfer to improve neuronal apoptosis and functional recovery after spinal cord injury. Stem Cell Res Ther 2021; 12(1): 289

[25] Song Z, Song H, Liu D, Yan B, Wang D, Zhang Y, Zhao X, Tian X, Yan C, Han Y. Overexpression of MFN2 alleviates sorafenib-induced cardiomyocyte necroptosis via the MAM-CaMKIIδ pathway in vitro and in vivo. Theranostics 2022; 12(3): 1267–1285

[26] Xu H, Yu W, Sun S, Li C, Zhang Y, Ren J. Luteolin attenuates doxorubicin-induced cardiotoxicity through promoting mitochondrial autophagy. Front Physiol 2020; 11: 113

[27] Sun S, Yu W, Xu H, Li C, Zou R, Wu NN, Wang L, Ge J, Ren J, Zhang Y. TBC1D15-Drp1 interaction-mediated mitochondrial homeostasis confers cardioprotection against myocardial ischemia/reperfusion injury. Metabolism 2022; 134: 155239

[28] Yang L, Xie P, Wu J, Yu J, Li X, Ma H, Yu T, Wang H, Ye J, Wang J, Zheng H. Deferoxamine treatment combined with sevoflurane postconditioning attenuates myocardial ischemia-reperfusion injury by restoring HIF-1/BNIP3-mediated mitochondrial autophagy in GK rats. Front Pharmacol 2020; 11: 6

[29] Wang X, Jiang Y, Zhang Y, Sun Q, Ling G, Jiang J, Li W, Tian X, Jiang Q, Lu L, Wang Y. The roles of the mitophagy inducer Danqi pill in heart failure: a new therapeutic target to preserve energy metabolism. Phytomedicine 2022; 99: 154009

[30] Kowaltowski AJ, Menezes-Filho SL, Assali EA, Gonçalves IG, Cabral-Costa JV, Abreu P, Miller N, Nolasco P, Laurindo FRM, Bruni-Cardoso A, Shirihai OS. Mitochondrial morphology regulates organellar Ca²⁺ uptake and changes cellular Ca²⁺ homeostasis. FASEB J 2019; 33(12): 13176–13188

[31] Zhu N, Huang B, Zhu L, Wang Y. Potential mechanisms of triptolide against diabetic cardiomyopathy based on network pharmacology analysis and molecular docking. J Diabetes Res 2021; 2021: 9944589

[32] Wold LE, Relling DP, Duan J, Norby FL, Ren J. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of Jak/STAT pathway. Hypertension 2002; 39(1): 69–74

[33] Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016; 134(1): 73–90

[34] Tong M, Zablocki D, Sadoshima J. The role of Drp1 in mitophagy and cell death in the heart. J Mol Cell Cardiol 2020; 142: 138–145

[35] Friedman JR, Nunnari J. Mitochondrial form and function. Nature 2014; 505(7483): 335–343

[36] Picca A, Mankowski RT, Burman JL, Donisi L, Kim JS, Marzetti E, Leeuwenburgh C. Mitochondrial quality control mechanisms as molecular targets in cardiac ageing. Nat Rev Cardiol 2018; 15(9): 543–554

[37] Kamerkar SC, Kraus F, Sharpe AJ, Pucadyil TJ, Ryan MT. Dynamin-related protein 1 has membrane constricting and severing abilities sufficient for mitochondrial and peroxisomal fission. Nat Commun 2018; 9(1): 5239

[38] Ikeda Y, Shirakabe A, Maejima Y, Zhai P, Sciarretta S, Toli J, Nomura M, Mihara K, Egashira K, Ohishi M, Abdellatif M, Sadoshima J. Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress. Circ Res 2015; 116(2): 264–278

[39] Ajoolabady A, Chiong M, Lavandero S, Klionsky DJ, Ren J. Mitophagy in cardiovascular diseases: molecular mechanisms, pathogenesis, and treatment. Trends Mol Med 2022; 28(10): 836–849

[40] Xu S, Wang P, Zhang H, Gong G, Gutierrez Cortes N, Zhu W, Yoon Y, Tian R, Wang W. CaMKII induces permeability transition through Drp1 phosphorylation during chronic β-AR stimulation. Nat Commun 2016; 7(1): 13189

[41] Jhun BS, O-Uchi J, Adaniya SM, Mancini TJ, Cao JL, King ME, Landi AK, Ma H, Shin M, Yang D, Xu X, Yoon Y, Choudhary G, Clements RT, Mende U, Sheu SS. Protein kinase D activation induces mitochondrial fragmentation and dysfunction in cardiomyocytes. J Physiol 2018; 596(5): 827–855

[42] Kageyama Y, Hoshijima M, Seo K, Bedja D, Sysa-Shah P, Andrabi SA, Chen W, Höke A, Dawson VL, Dawson TM, Gabrielson K, Kass DA, Iijima M, Sesaki H. Parkin-independent mitophagy requires Drp1 and maintains the integrity of mammalian heart and brain. EMBO J 2014; 33(23): 2798–2813

[43] Zhang H, Wang P, Bisetto S, Yoon Y, Chen Q, Sheu SS, Wang W. A novel fission-independent role of dynamin-related protein 1 in cardiac mitochondrial respiration. Cardiovasc Res 2017; 113(2): 160–170

[44] Wasiak S, Zunino R, McBride HM. Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. J Cell Biol 2007; 177(3): 439–450

[45] Shou J, Huo Y. PINK1 phosphorylates Drp1^S616 to improve mitochondrial fission and inhibit the progression of hypertension-induced HFpEF. Int J Mol Sci 2022; 23(19): 11934

[46] Chaanine AH, Joyce LD, Stulak JM, Maltais S, Joyce DL, Dearani JA, Klaus K, Nair KS, Hajjar RJ, Redfield MM. Mitochondrial morphology, dynamics, and function in human pressure overload or ischemic heart disease with preserved or reduced ejection fraction. Circ Heart Fail 2019; 12(2): e005131

[47] Favaro G, Romanello V, Varanita T, Andrea Desbats M, Morbidoni V, Tezze C, Albiero M, Canato M, Gherardi G, De Stefani D, Mammucari C, Blaauw B, Boncompagni S, Protasi F, Reggiani C, Scorrano L, Salviati L, Sandri M. DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass. Nat Commun 2019; 10(1): 2576

[48] Zhao Q, Lu D, Wang J, Liu B, Cheng H, Mattson MP, Cheng A. Calcium dysregulation mediates mitochondrial and neurite outgrowth abnormalities in SOD2 deficient embryonic cerebral cortical neurons. Cell Death Differ 2019; 26(9): 1600–1614

[49] Morciano G, Rimessi A, Patergnani S, Vitto VAM, Danese A, Kahsay A, Palumbo L, Bonora M, Wieckowski MR, Giorgi C, Pinton P. Calcium dysregulation in heart diseases: targeting calcium channels to achieve a correct calcium homeostasis. Pharmacol Res 2022; 177: 106119

[50] Siri-Angkul N, Dadfar B, Jaleel R, Naushad J, Parambathazhath J, Doye AA, Xie LH, Gwathmey JK. Calcium and heart failure: how did we get here and where are we going? Int J Mol Sci 2021; 22(14): 7392 doi:10.3390/ijms22147392

[51] Williams GS, Boyman L, Chikando AC, Khairallah RJ, Lederer WJ. Mitochondrial calcium uptake. Proc Natl Acad Sci USA 2013; 110(26): 10479–10486

[52] Garbincius JF, Elrod JW. Mitochondrial calcium exchange in physiology and disease. Physiol Rev 2022; 102(2): 893–992

[53] Miranda-Silva D, Wüst RCI, Conceição G, Gonçalves-Rodrigues P, Gonçalves N, Gonçalves A, Kuster DWD, Leite-Moreira AF, van der Velden J, de Sousa Beleza JM, Magalhães J, Stienen GJM, Falcão-Pires I. Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction. Acta Physiol (Oxf) 2020; 228(3): e13378

RIGHTS & PERMISSIONS

Higher Education Press